Category: 875444-08-9

Synthetic Route of 875444-08-9, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2. In a Patent£¬once mentioned of 875444-08-9

PROCESS FOR A CETP INHIBITOR

An efficient process is disclosed for producing the compound of formula I, which is the CETP inhibitor anacetrapib, which raises HDL-cholesterol and reduces LDL-cholesterol in human patients and may be effective for treating or reducing the risk of developing atherosclerosis:.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 875444-08-9

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2763NO – PubChem

 

Synthetic Route of 875444-08-9, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2. In a Article£¬once mentioned of 875444-08-9

Synthesis and crystal structure of (4S,5R)-5-[3,5-BIS(trifluoromethyl) phenyl]-4-methyl-1,3-oxazolidin-2-one

The crystal structure of the (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4- methyl-1,3-oxazolidin-2-one has been determined by single crystal X-ray diffraction method. The compound crystallizes in the monoclinic system, space group P2(1) with a = 11.867(4) A, b = 5.6968(19) A, c = 20.258(7) A, alpha = 90.00, beta = 91.866(4), gamma = 90.00, Z = 4, V = 1368.8(8) A3, Dx = 1.520 Mg/m3, F (000) = 632, mu(MoKalpha) = 0.157 mm-1, R = 0.0562 and wR = 0.1744 for 3675 reflections with I > 2sigma(I). X-Ray analysis reveals that the benzene and oxazolidin rings are non-coplanar. The oxazolidin ring displays a twist conformation. The two molecules interact with each other by two strong N-H¡¤¡¤¡¤O hydrogen bonds. Herein, we report the synthesis and crystal structure of (4S,5R)-5-[3,5- bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 875444-08-9

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2781NO – PubChem

 

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, Quality Control of (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2

SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Quality Control of (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 875444-08-9, in my other articles.

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2766NO – PubChem

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 875444-08-9, name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, introducing its new discovery. Safety of (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors

SAR studies of the substitution effect on the central phenyl ring of the biphenyl scaffold were carried out using anacetrapib (9a) as the benchmark. The results revealed that the new analogs with substitutions to replace trifluoromethyl (9a) had a significant impact on CETP inhibition in vitro. In fact, analogs with some small groups were as potent or more potent than the CF3 derivative for CETP inhibition. Five of these new analogs raised HDL-C significantly (>20 mg/dL). None of them however was better than anacetrapib in vivo. The synthesis and biological evaluation of these CETP inhibitors are described.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 875444-08-9, and how the biochemistry of the body works.Safety of (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2783NO – PubChem

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 875444-08-9, name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, introducing its new discovery. name: (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various CETP enzyme activity- or HDL cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 875444-08-9, and how the biochemistry of the body works.name: (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2773NO – PubChem

 

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Recommanded Product: (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 875444-08-9, name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one. In an article£¬Which mentioned a new discovery about 875444-08-9

PROCESS FOR SYNTHESIZING A CETP INHIBITOR

An efficient process is disclosed for producing a compound that is an inhibitor of CETP. The next to last step of the process is the coupling of an oxazolidinone derivative and a triphenyl compound to provide the methyl ester of a compound which is hydrolyzed to the active CETP inhibitor. (1)

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 875444-08-9, help many people in the next few years.Recommanded Product: (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2772NO – PubChem

 

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, Recommanded Product: 875444-08-9, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2

POLYMER FORMULATIONS OF CETP INHIBITORS

A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer; and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Recommanded Product: 875444-08-9, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 875444-08-9, in my other articles.

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2764NO – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 875444-08-9, molcular formula is C12H9F6NO2, introducing its new discovery. , 875444-08-9

SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 875444-08-9, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 875444-08-9

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2765NO – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 875444-08-9, molcular formula is C12H9F6NO2, introducing its new discovery. , 875444-08-9

CETP INHIBITORS

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or R2 is also a cyclic group.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, 875444-08-9, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 875444-08-9

Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2758NO – PubChem

 

875444-08-9, The molecularity of an elementary reaction is the number of molecules that collide during that step in the mechanism. If there is only a single reactant molecule in an elementary reaction, that step is designated as unimolecular. 875444-08-9, name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one. A new synthetic method of this compound is introduced below.

The chiral intermediate (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one (compound of formula XV; cf. also compound 11 in Scheme 3) (280 mg) prepared by procedure of WO 2007/005572 is dissolved in DMF (30 mL) and cooled to -15C. 2 M NaHMDS (3.90 mL, 1.05 eq) was then added over 1 h, followed by addition of the biaryl chloride EBFCI (270 mg) in DMF (5 mL), maintaining the internal temperature below-10 C. The mixture was warmed to +12 C and was aged until complete conversion took place. Then 5M HCl (3.5 mL) was added, followed by 20 mL of 10% IPAC/Heptanes and 40 mL of water, keeping the temperature between 10C and 20C throughout. The layers were cut and the organic layer was washed twice with 20 mL of 1/1 DMF/water followed by two 15 mL water washes. The organic layer was then removed under reduced pressure and the resulting residue was purified by flash chromatography (EtOActhexanes) to remove the excess oxazolidinone (compound of formula XV). The pure (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5′-ethyl-4′-fluoro-2′-methoxy-4-(trifluoromethyl)biphenyl-2-yl)methyl)-4-methyloxazolidin-2-one (DMAP, compound of formula XII”) was obtained as a colorless oil (388 mg, 80%).

Any one of these steps may be slow and thus may serve as the rate determining step. In general, however, in the presence of the catalyst, the overall rate of the reaction is faster than it would be if the reactants were in the gas or liquid phase.

Reference£º
Patent; LEK Pharmaceuticals d.d.; EP2468736; (2012); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem